ASH 2022 | An overview of the current and future treatment landscape for MPNs
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, shares some insights into the current and future treatment landscape for patients with myeloproliferative neoplasms (MPNs). Dr Gerds highlights that JAK inhibitors, combination therapies, and novel agents such as bispecific antibodies, monoclonal antibodies and vaccination therapies are promising options for MPN patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kratos Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Imago BioSciences: Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Accurate Pharmaceuticals: Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Morphosys/Constellation: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; PharmaEssentia: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
